This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Coagulation and haemorrhagic disorders
  • /
  • Antidotes for reversal of direct oral anticoagulan...

Antidotes for reversal of direct oral anticoagulants.

Read time: 1 mins
Published:11th Sep 2019
Author: Dobesh PP, Bhatt SH, Trujillo TC, Glaubius K.
Availability: Pay for access, or by subscription
Ref.:Pharmacol Ther. 2019:107405.

The main advantage of the direct oral anticoagulants over vitamin K antagonists is reduced rates of major bleeding, especially intracranial hemorrhage. While use of different clotting factor supplements have been used in patients with direct oral anticoagulant induced major bleeding or when there is need for urgent surgery, the lack of preclinical and clinical data are concerning. Idarucizumab is a specific antibody developed with a 350-fold greater affinity for dabigatran than its pharmacologic target thrombin.

Andexanet is a modified factor Xa molecule that binds the direct and indirect Xa inhibitors without being enzymatically active. Ciraparantag, has potential to reverse the anticoagulant activity of multiple agents. The pharmacology, preclinical, and clinical data that have developed these specific antidotes are reviewed in this manuscript.


Read abstract on library site

Access full article